| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The specific molecular target of 3,6-Dihydroxyxanthone is not clearly defined. Its anticancer activity is thought to be related to its ability to inhibit protein and DNA synthesis. The mechanism of this inhibition is not yet fully understood but may be related to its ability to react with nitrogen atoms or its hydroxyl groups, which are found in proteins and DNA. As a xanthone derivative, it may also interact with various enzymes or signaling pathways involved in cell proliferation.
|
|---|---|
| ln Vitro |
3,6-DiHydroxyxanthone (Compound 3) (3.906-1000 µg/mL; 24 hours) has cytotoxic action against Vero and WiDR cell lines, with IC50 values of 1280.9 µM and 785.58, respectively [1].
In vitro, 3,6-Dihydroxyxanthone exhibits cytotoxic activity against cancer cell lines. It has been tested against WiDR (colon cancer) and Vero (kidney epithelial) cell lines, with IC₅₀ values of 785.58 μM and 1280.9 μM, respectively, after 24 hours of treatment at concentrations ranging from 3.906 to 1000 μg/mL. These data indicate that the compound has moderate cytotoxic activity. Its mechanism involves inhibition of protein and DNA synthesis. |
| ln Vivo |
Specific in vivo activity data for 3,6-Dihydroxyxanthone are not provided in the available sources. While the compound exhibits in vitro anticancer activity, no in vivo studies in animal models are described. Further research would be needed to evaluate its efficacy, pharmacokinetics, and safety in vivo. Its potential for cancer research has been suggested based on its in vitro activity.
|
| Enzyme Assay |
A cell-free assay for 3,6-Dihydroxyxanthone is not specifically described in the available sources. The compound's activity is characterized through cell-based cytotoxicity assays. Its effects on protein and DNA synthesis could be measured in cell-free systems using radiolabeled precursors, but specific protocols are not provided. The compound's ability to react with nitrogen atoms or hydroxyl groups suggests potential reactivity with biomolecules.
|
| Cell Assay |
Cytotoxicity assay[1]
Cell Types: WiDR and Vero cell lines Tested Concentrations: 3.906, 7.813, 15.625, 31.25, 62.5, 125, 250 and 500 µg/mL (WiDR cell line) 7.813, 15.625, 31.25, 62.5, 125, 250 , 500 and 1000 µg/mL (Vero cell line) Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited cell activity with IC50 values of 785.58 and 1,280.9 µM for WiDR and Vero cell lines. Cellular assays for 3,6-Dihydroxyxanthone typically involve assessing its cytotoxic effects on cancer cell lines. In one study, WiDR and Vero cells were treated with the compound at concentrations of 3.906-1000 μg/mL for 24 hours. Cell viability was then measured, and IC₅₀ values of 785.58 μM (WiDR) and 1280.9 μM (Vero) were determined. This type of assay is standard for evaluating the antiproliferative activity of potential anticancer compounds. |
| Animal Protocol |
Specific in vivo animal实验 protocols for 3,6-Dihydroxyxanthone are not available from the provided sources. As a compound with in vitro anticancer activity, potential in vivo studies could involve xenograft models in mice, where tumor-bearing animals would be treated with the compound to evaluate tumor growth inhibition. However, no such data or protocols are described in the accessible literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of 3,6-Dihydroxyxanthone are not reported in the available sources. As a naturally occurring xanthone derivative, its absorption, distribution, metabolism, and excretion (ADME) profiles have not been characterized. The compound is a solid at room temperature. Standard storage conditions for research compounds apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for 3,6-Dihydroxyxanthone are not provided in the available sources. The compound exhibits cytotoxic activity against cancer cell lines, but its selectivity and safety profile have not been established. As with all research compounds, it is intended for research use only and not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that 3,6-dihydroxy-9H-xanthon-9-one has been found in Rhachidosorus mesosorus, and relevant data are available for reference.
3,6-Dihydroxyxanthone (CAS: 1214-24-0) is a naturally occurring xanthone derivative with reported anticancer activity. It is also known as compound 3. The compound has been shown to inhibit protein and DNA synthesis, which may underlie its cytotoxic effects. It exhibits moderate cytotoxicity against WiDR and Vero cell lines with IC₅₀ values of 785.58 μM and 1280.9 μM, respectively. It is not an approved drug and has not undergone clinical trials. Its primary value lies in its use as a tool for studying the mechanisms of anticancer activity. |
| Molecular Formula |
C13H8O4
|
|---|---|
| Molecular Weight |
228.2002
|
| Exact Mass |
228.042
|
| CAS # |
1214-24-0
|
| PubChem CID |
5749322
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3036 g/cm3
|
| Boiling Point |
330 °C
|
| Melting Point |
395 °C
|
| LogP |
2.357
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
289
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
POARTHFLPKAZBQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H8O4/c14-7-1-3-9-11(5-7)17-12-6-8(15)2-4-10(12)13(9)16/h1-6,14-15H
|
| Chemical Name |
3,6-dihydroxyxanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3821 mL | 21.9106 mL | 43.8212 mL | |
| 5 mM | 0.8764 mL | 4.3821 mL | 8.7642 mL | |
| 10 mM | 0.4382 mL | 2.1911 mL | 4.3821 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
